AlTi Global Inc. Has $231,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

AlTi Global Inc. reduced its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 97.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,091 shares of the biopharmaceutical company's stock after selling 160,244 shares during the quarter. AlTi Global Inc.'s holdings in Bristol-Myers Squibb were worth $231,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $1,989,525,000. Wellington Management Group LLP boosted its position in Bristol-Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after buying an additional 5,827,317 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $257,618,000. Schroder Investment Management Group boosted its holdings in Bristol-Myers Squibb by 49.7% in the fourth quarter. Schroder Investment Management Group now owns 11,413,428 shares of the biopharmaceutical company's stock valued at $639,837,000 after purchasing an additional 3,787,075 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Bristol-Myers Squibb by 16.2% during the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock worth $1,394,677,000 after acquiring an additional 3,431,248 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Down 1.1 %

Shares of NYSE BMY traded down $0.50 during mid-day trading on Friday, reaching $46.38. The company had a trading volume of 14,905,695 shares, compared to its average volume of 13,078,510. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock's 50 day moving average is $54.80 and its 200-day moving average is $56.23. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market capitalization of $94.39 billion, a PE ratio of -10.49, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the previous year, the company earned ($4.40) earnings per share. The company's revenue was down 5.6% compared to the same quarter last year. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.35%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BMY shares. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.